专利检索 ap:("AstraZeneca AB") AND inv:"Jeffrey JOHANNES" 第 1 页

1.

发明申请
MCL-1 INHIBITORS AND METHODS OF USE THEREOF 审中-公开

公开(公告)号：US20190185485A1

公开(公告)日：2019-06-20

申请号：US16223538

申请日：2018-12-18

申请人： AstraZeneca AB

发明人： Alexander HIRD , Matthew BELMONTE , Wenzhan YANG , Paul SECRIST , Daniel ROBBINS , Steven KAZMIRSKI , Dedong WU , Bo PENG , Jeffrey JOHANNES , Michelle LAMB , Qing YE , Xiaolan ZHENG

IPC分类号： C07D497/22 , C07D515/22

CPC分类号： C07D497/22 , C07D515/22

摘要： Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15,016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

2.

发明申请
MCL-1 INHIBITORS AND METHODS OF USE THEREOF 有权

公开(公告)号：US20170305926A1

公开(公告)日：2017-10-26

申请号：US15493210

申请日：2017-04-21

申请人： AstraZeneca AB

发明人： Alexander HIRD , Wenzhan YANG , Daniel ROBBINS , Steven KAZMIRSKI , Dedong WU , Bo PENG , Jeffrey JOHANNES , Michelle LAMB

IPC分类号： C07D497/22

CPC分类号： C07D497/22 , C07D515/22

摘要： Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

3.

发明申请
MCL-1 INHIBITORS AND METHODS OF USE THEREOF 有权

公开(公告)号：US20210230184A1

公开(公告)日：2021-07-29

申请号：US17111896

申请日：2020-12-04

申请人： AstraZeneca AB

发明人： Alexander HIRD , Matthew BELMONTE , Wenzhan YANG , Paul SECRIST , Daniel ROBBINS , Steven KAZMIRSKI , Dedong WU , Bo PENG , Jeffrey JOHANNES , Michelle LAMB , Qing YE , XiaoLan ZHENG

IPC分类号： C07D497/22 , C07D515/22

摘要： Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

4.

发明申请
MCL-1 INHIBITORS AND METHODS OF USE THEREOF 审中-公开

公开(公告)号：US20180155362A1

公开(公告)日：2018-06-07

申请号：US15790660

申请日：2017-10-23

申请人： AstraZeneca AB

发明人： Alexander HIRD , Matthew BELMONTE , Wenzhan YANG , Paul SECRIST , Daniel ROBBINS , Steven KAZMIRSKI , Dedong WU , Bo PENG , Jeffrey JOHANNES , Michelle LAMB , Qing YE , Xiaolan ZHENG

IPC分类号： C07D497/22

CPC分类号： C07D497/22 , C07D515/22

摘要： Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.